MV Capital Management Inc. Increases Stock Holdings in Pfizer Inc. (NYSE:PFE)

MV Capital Management Inc. increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 25.3% during the 1st quarter, Holdings Channel reports. The institutional investor owned 39,036 shares of the biopharmaceutical company’s stock after purchasing an additional 7,887 shares during the period. MV Capital Management Inc.’s holdings in Pfizer were worth $1,414,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. BlackRock Inc. lifted its position in Pfizer by 2.2% during the 1st quarter. BlackRock Inc. now owns 405,733,970 shares of the biopharmaceutical company’s stock worth $14,699,742,000 after acquiring an additional 8,760,458 shares during the period. Bank of New York Mellon Corp lifted its position in Pfizer by 12.1% during the 4th quarter. Bank of New York Mellon Corp now owns 64,756,839 shares of the biopharmaceutical company’s stock worth $2,383,700,000 after acquiring an additional 6,965,496 shares during the period. Norges Bank acquired a new stake in Pfizer during the 4th quarter worth about $2,219,532,000. Morgan Stanley lifted its position in Pfizer by 16.4% during the 4th quarter. Morgan Stanley now owns 53,610,111 shares of the biopharmaceutical company’s stock worth $1,973,389,000 after acquiring an additional 7,540,245 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in Pfizer by 5.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 42,009,283 shares of the biopharmaceutical company’s stock worth $1,546,362,000 after acquiring an additional 2,012,367 shares during the period. 64.22% of the stock is owned by institutional investors.

NYSE:PFE traded down $0.50 during trading hours on Friday, hitting $40.18. 226,515 shares of the stock were exchanged, compared to its average volume of 30,701,137. Pfizer Inc. has a 52-week low of $31.61 and a 52-week high of $43.08. The business’s fifty day simple moving average is $38.76. The company has a current ratio of 1.48, a quick ratio of 1.16 and a debt-to-equity ratio of 0.51. The firm has a market cap of $224.92 billion, a P/E ratio of 20.76, a P/E/G ratio of 1.42 and a beta of 0.74.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 4th. The biopharmaceutical company reported $0.93 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.78 by $0.15. Pfizer had a return on equity of 24.55% and a net margin of 22.09%. The company had revenue of $14.58 billion during the quarter, compared to analyst estimates of $13.41 billion. During the same period in the previous year, the business earned $0.80 EPS. Pfizer’s quarterly revenue was up 44.6% on a year-over-year basis. As a group, sell-side analysts expect that Pfizer Inc. will post 3.69 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, June 4th. Stockholders of record on Friday, May 7th were given a $0.39 dividend. The ex-dividend date was Thursday, May 6th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 3.88%. Pfizer’s dividend payout ratio (DPR) is presently 70.27%.

A number of analysts have commented on PFE shares. Mizuho reaffirmed a “neutral” rating and set a $42.00 price target on shares of Pfizer in a research report on Wednesday, May 12th. Morgan Stanley boosted their price objective on Pfizer from $38.00 to $42.00 and gave the company an “equal weight” rating in a report on Monday, May 10th. SVB Leerink boosted their price objective on Pfizer from $39.00 to $43.00 and gave the company a “market perform” rating in a report on Wednesday, May 5th. JPMorgan Chase & Co. set a $40.00 price objective on Pfizer and gave the company a “neutral” rating in a report on Monday, May 24th. Finally, TheStreet raised Pfizer from a “c+” rating to a “b-” rating in a report on Monday, May 3rd. Twelve investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $39.73.

In other news, SVP Jennifer B. Damico sold 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, May 5th. The stock was sold at an average price of $40.82, for a total value of $102,050.00. Following the completion of the sale, the senior vice president now directly owns 13,748 shares in the company, valued at $561,193.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.05% of the stock is owned by corporate insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.

Further Reading: Compound Annual Growth Rate (CAGR)

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.